NCT06461533

A Survey of Susoctocog Alfa (Genetical Recombination) in Participants With Acquired Haemophilia A

General Use-results Survey of OBIZER for I.V. Injection (All-case Surveillance)

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 25 (estimated)
• Sponsor: Takeda · Industry
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

This study is a survey in Japan of Susoctocog Alfa (Genetical Recombination) intravenous injection used to treat participants with bleeding events of acquired Haemophilia A (AHA). The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. The main aim of the study is to check for side effects related from Susoctocog Alfa (Genetical Recombination) intravenous injection and to check if Susoctocog Alfa (Genetical Recombination) intravenous injection improves bleeding events of AHA. During the study, participants with AHA will take Susoctocog Alfa (Genetical Recombination) intravenous injection according to their clinic's standard practice. The study doctors will check for side effects from Susoctocog Alfa (Genetical Recombination) intravenous injection for up to 90 days after the last dose of study drug or until discontinued (varied from participant to participant).

Conditions

• Acquired Hemophilia A

Interventions

Type	Name	Description
DRUG	Susoctocog Alfa (Genetical Recombination)	Susoctocog Alfa (Genetical Recombination), Intravenous injection

Timeline

• Start date: 2024-06-10
• Primary completion: 2029-10-31
• Completion: 2029-10-31
• First posted: 2024-06-17
• Last updated: 2025-06-04

Locations

1 site across 1 country: Japan